{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:48:31Z","timestamp":1766087311988},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"\n Background:<\/jats:title>\n After national recommendations, palivizumab is administered in Germany to high-risk infants to prevent hospitalizations related to respiratory syncytial virus (RSV) infection. Limited data are available to characterize those children who receive palivizumab in 2 consecutive RSV seasons.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This was a comparative analysis of data from a postmarketing observational study (German SYNAGIS Registry, AbbVie Germany GmbH & Co.KG, Wiesbaden) detailing RSV-related risk factors and main indications for palivizumab in 920 children who received at \u22651 palivizumab injection in a second season between 2010 and 2016 [second season population (SSP)].<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Median birth weight and gestational age at birth as well as the proportion of children with hemodynamically significant congenital heart disease, with any form of chronic lung disease of prematurity or with any form of neuromuscular impairment, were significantly higher in the SSP. Accordingly, hemodynamically significant congenital heart disease, chronic lung disease and other reasons (including neuromuscular impairment) and not prematurity were the main indications for palivizumab in the SSP. The RSV-related hospitalization rate confirmed by viral testing in the SSP (receiving palivizumab prophylaxis) was 0.9%. No deaths due to RSV were reported.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Second season recipients of palivizumab differ from one season recipients of palivizumab in terms of risk factors and main indications for prophylaxis. Keeping in mind the limitations of an uncontrolled prospective observational study, these results support the effectiveness of palivizumab (concerning the RSV rehospitalization rate) and do not reveal new safety alerts in a large SSP.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/inf.0000000000002133","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T22:18:19Z","timestamp":1531779499000},"page":"987-991","source":"Crossref","is-referenced-by-count":3,"title":["Risk Factors and Main Indications for Palivizumab Prophylaxis in a Second Season Population"],"prefix":"10.1097","volume":"37","author":[{"given":"Arne","family":"Simon","sequence":"first","affiliation":[{"name":"Pediatric Hematology and Oncology, Children\u2019s Hospital Medical Center, University Hospital of Saarland, Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Gehrmann","sequence":"additional","affiliation":[{"name":"Medical Unit Leader, Department of Medical Affairs, AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"Wagenpfeil","sequence":"additional","affiliation":[{"name":"Institutes for Medical Biometry, Epidemiology and Medical Informatics (IMBEI), Saarland University, Campus Homburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Wagenpfeil","sequence":"additional","affiliation":[{"name":"Institutes for Medical Biometry, Epidemiology and Medical Informatics (IMBEI), Saarland University, Campus Homburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/BF01957502","article-title":"The clinical picture presented by premature neonates infected with the respiratory syncytial virus.","volume":"154","author":"Forster","year":"1995","journal-title":"Eur J Pediatr"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.","volume":"368","author":"Blanken","year":"2013","journal-title":"N Engl J Med"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1128\/AAC.06446-11","article-title":"Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.","volume":"56","author":"Robbie","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00431-017-2849-4","article-title":"First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).","volume":"176","author":"Wang","year":"2017","journal-title":"Eur J Pediatr"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ppul.10288","article-title":"Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.","volume":"35","author":"Parnes","year":"2003","journal-title":"Pediatr Pulmonol"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1097\/01.inf.0000053885.34703.84","article-title":"Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.","volume":"22","author":"Romero","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R9-20230912","first-page":"78","article-title":"Compliance of pediatric centers to Italian Society of Neonatology recommendations on prevention of respiratory syncytial virus infection: results of the second season of the Previeni Study.","volume":"27","author":"Macagno","year":"2005","journal-title":"Pediatr Med Chir"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/01.inf.0000183938.33484.bd","article-title":"Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.","volume":"24","author":"Null","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20230912","article-title":"Use of palivizumab in Germany - report from the German Synagis Registry 2009 - 2016.","author":"Simon","year":"2018 Apr 16","journal-title":"Klin Padiatr"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"917068","DOI":"10.1155\/2013\/917068","article-title":"Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries.","volume":"2013","author":"Paes","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00002018-200326040-00005","article-title":"Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection.","volume":"26","author":"Lacaze-Masmonteil","year":"2003","journal-title":"Drug Saf"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201810000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:14:55Z","timestamp":1694556895000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201810000-00006"}},"subtitle":["Results From the German Synagis Registry 2009\u20132016"],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002133","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}